Niagen Bioscience, Inc. (NAGE)
| Market Cap | 1.09B |
| Revenue (ttm) | 107.93M |
| Net Income (ttm) | 14.11M |
| Shares Out | 78.94M |
| EPS (ttm) | 0.18 |
| PE Ratio | 77.00 |
| Forward PE | 127.24 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 822,613 |
| Open | 13.88 |
| Previous Close | 13.88 |
| Day's Range | 13.31 - 14.14 |
| 52-Week Range | 2.31 - 14.49 |
| Beta | 2.08 |
| Analysts | Strong Buy |
| Price Target | 16.67 (+20.97%) |
| Earnings Date | Aug 6, 2025 |
About NAGE
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and ph... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for NAGE stock is "Strong Buy." The 12-month stock price forecast is $16.67, which is an increase of 20.97% from the latest price.
News
Niagen Bioscience to Participate in the BIO 2025 International Convention
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the...
Niagen Bioscience: High Conviction, High Expectations
Niagen Bioscience's stock price is breaking out with strong fundamentals, proprietary IP, and a leadership position in the NAD+ longevity market. Revenue and margins are rising, driven by Tru Niagen e...
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the...
Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #InvestorRelations--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a fo...
Niagen Bioscience, Inc. (NAGE) Q1 202 Earnings Call Transcript
Niagen Bioscience, Inc. Q1 2025 - Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Wesley Yu - VP of Finance Rob Fried - CEO Ozan Pamir - CFO Andrew Shao - SVP, Scientific & Regula...
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025. First Quarter 2025 Financial and Recent Opera...
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on ...
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on ...
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on ...
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on ...
Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on ...
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #IP--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the scie...
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on ...
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #InvestorRelations--ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging,...
ChromaDex to Present at the 37th Annual Roth Conference
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today ...
ChromaDex Capitalizes On Longevity Boom But Valuation Remains High
ChromaDex Corporation shows strong revenue growth and profitability, driven by its NAD+ precursors and flagship product Niagen, despite high valuation and execution risks. Record-breaking financial pe...
ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript
ChromaDex Corporation (NASDAQ:CDXC) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Ben Shamsian - Vice President, Lytham Partners, Investor Relations Rob Fried - Chief...
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results. Fourth Quarter 2024 Total net sales of $29.1 mil...
ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #2024Earnings--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces ...
ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today ...
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) proudly announces its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.'s annual B...
ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, announ...
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announc...
ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript
ChromaDex Corporation (NASDAQ:CDXC) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Ben Shamsian - IR Rob Fried - CEO Ozan Pamir - CFO Andrew Shao - SVP, Scientific ...
ChromaDex Corporation Reports Third Quarter 2024 Financial Results
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024. Third Quarter 2024 Financial and Recent Operational Hi...